Teva Pharmaceuticals has been told to sell certain rights and assets if the US Federal Trade Commission is to clear its $6.8bn acquisition of Cephalon.

The assets include selling all rights related to the company’s generic version of Actiq and muscle relaxant Amrix to US-based Par Pharmaceuticals.

Teva must also grant an undisclosed company non-exclusive US rights to market a generic version of Cephalon’s Provigil medication, used to treat sleep disorders.

All divestitures must be completed within ten days of the closing of Teva’s acquisition which, subject to EU approval, is due within the next week.